ARCHIVES

Phase 0 Trials Signal FDA’s New Reliance On Biomarkers For Drug Development.

This article is from The Cancer Letter archive.

Vol. 32 No. 01 | January 13, 2006

Download PDF Visit The Full Archive

Related Articles

Majority Of Americans Would Consider Participating In Clinical Trials, Study Finds

March 28, 2003

Gleevec Produces 59% Response Rate In Gastrointestinal Stromal Tumors

May 25, 2001

In Brief: Adjuvant Chemotherapy Standard Practice For Breast Cancer At Milan, Bonadonna Says

May 7, 1976

ACCC Planning Session Considers Community Impact

August 31, 1979

NCI Offers Fellowship Training In Epidemiology & Genetics.

February 18, 2000

PET Response Can Predict Increased Survival In Patients

April 27, 2012